Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120084) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-1894 in Healthy Subjects: A Randomised, Double-Blind, Placebo-Controlled Phase I Clinical Study' on March 9.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: West China Hospital of Sichuan University

Condition: healthy person

Intervention: Single-dose escalation in healthy subjects group:The study prespecified five dose groups: 150 mg, 300 mg, 600 mg, 1200 mg, and 1800 mg (optional). During the trial, single-dose escalation may be adjusted based on accumulated safety, tolerability,...